ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas.

作者: Xing Fan , Yongheng Wang , Chuanbao Zhang , Li Liu , Sen Yang

DOI: 10.3390/IJMS17091276

关键词:

摘要: The A disintegrin and metalloproteinase 9 (ADAM9) protein has been suggested to promote carcinoma invasion appears be overexpressed in various human cancers. However, its role rarely investigated gliomas and, thus, the current study we have evaluated ADAM9 expression examined relevance of prognosis glioma patients. Clinical characteristics, RNA sequence data, case follow-ups were reviewed for 303 patients who had histological, confirmed gliomas. between lower-grade (LGG) glioblastoma (GBM) was compared association with progression-free survival (PFS) overall (OS) assessed evaluate prognostic value. Our data that GBM significantly higher comparison LGG (p < 0.001, t-test). In addition, among patients, aggressive astrocytic tumors displayed than oligodendroglial Moreover, high also correlated poor clinical outcome 0.001 p log-rank test, PFS OS, respectively) Further, multivariate analysis an independent marker = 0.002 0.003, respectively). These results suggest mRNA is associated tumor grade histological type can serve as factor, specifically

参考文章(51)
Kyung-Eun Kim, Hyunkeun Song, Candace Hahm, Sun Young Yoon, Sunyoung Park, Ha-reum Lee, Dae Young Hur, Taesung Kim, Cherl-hyun Kim, Sa Ik Bang, Jung-Wook Bang, Hyunjeong Park, Dae-Ho Cho, Expression of ADAM33 Is a Novel Regulatory Mechanism in IL-18-Secreted Process in Gastric Cancer Journal of Immunology. ,vol. 182, pp. 3548- 3555 ,(2009) , 10.4049/JIMMUNOL.0801695
David N. Louis, WHO classification of tumours of the central nervous system International Agency for Research on Cancer. ,(2007)
Cancer Genome Atlas Research Network, None, Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. The New England Journal of Medicine. ,vol. 372, pp. 2481- 2498 ,(2015) , 10.1056/NEJMOA1402121
W Wechsler, L Liu, L Liu, G Reifenberger, G Reifenberger, J Reifenberger, C D James, V P Collins, V P Collins, Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. American Journal of Pathology. ,vol. 145, pp. 1175- 1190 ,(1994)
Caroline O'Shea, Norman McKie, Yvonne Buggy, Catherine Duggan, Arnold DK Hill, Enda McDermott, Niall O'Higgins, Michael J Duffy, None, Expression of ADAM-9 mRNA and protein in human breast cancer. International Journal of Cancer. ,vol. 105, pp. 754- 761 ,(2003) , 10.1002/IJC.11161
Catherine A. Formolo, Russell Williams, Heather Gordish-Dressman, Tobey J. MacDonald, Norman H. Lee, Yetrib Hathout, Secretome Signature of Invasive Glioblastoma Multiforme Journal of Proteome Research. ,vol. 10, pp. 3149- 3159 ,(2011) , 10.1021/PR200210W
R Grützmann, J Lüttges, B Sipos, O Ammerpohl, F Dobrowolski, I Alldinger, S Kersting, D Ockert, R Koch, H Kalthoff, H K Schackert, H D Saeger, G Klöppel, C Pilarsky, ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma British Journal of Cancer. ,vol. 90, pp. 1053- 1058 ,(2004) , 10.1038/SJ.BJC.6601645
Xing Fan, Yin-yan Wang, Chuan-bao Zhang, Gan You, Ming-yang Li, Lei Wang, Tao Jiang, Expression of RINT1 predicts seizure occurrence and outcomes in patients with low-grade gliomas. Journal of Cancer Research and Clinical Oncology. ,vol. 141, pp. 729- 734 ,(2015) , 10.1007/S00432-014-1827-8
Uwe Lendeckel, Jana Kohl, Marco Arndt, Stacy Carl-McGrath, Hans Donat, Christoph R�cken, Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. Journal of Cancer Research and Clinical Oncology. ,vol. 131, pp. 41- 48 ,(2005) , 10.1007/S00432-004-0619-Y
Giovanna M. D'Abaco, Ken Ng, Lucy Paradiso, Nathan J. Godde, Andrew Kaye, Ulrike Novak, ADAM22, expressed in normal brain but not in high-grade gliomas, inhibits cellular proliferation via the disintegrin domain. Neurosurgery. ,vol. 58, pp. 179- 186 ,(2006) , 10.1227/01.NEU.0000192363.84287.8B